Industry News

Intrexon Corp., Alkermes PLC, BioScrip Inc., and Heartware International Inc.."/>
Healthcare Sector Equities Under Review -- Intrexon, Alkermes, BioScrip, and Heartware Intl.
Trovagene, Inc., a developer of circulating tumor DNA molecular diagnostics, announced today that it will report financial results for the second quarter ended June 30, 2016 on Thursday, August 4, 2016 at 4:00 p.m. Eastern Daylight Time. Trovagene's senior management team will host a conference call on Thursday, August 4, 2016 at 5:00 p.m. Eastern Daylight Time to discuss the results and update investors on the Company's progress."/>
Trovagene Schedules Release of Second Quarter 2016 Financial Results and Investor Conference Call
Cardiome Pharma Corp. announced today the pricing of its previously announced underwritten public offering of 10,000,000 common shares from treasury at a price to the public of US $3.00 per common share, for aggregate gross proceeds to the Company of US $30,000,000, before deducting the underwriting commission and estimated Offering expenses payable by the Company. In addition, Cardiome has also granted the underwriters of the..."/>
Cardiome Announces Pricing of Public Offering of 10,000,000 Common Shares
Cardiome Pharma Corp. announced today the pricing of its previously announced underwritten public offering of 10,000,000 common shares from treasury at a price to the public of US $3.00 per common share, for aggregate gross proceeds to the Company of US $30,000,000, before deducting the underwriting commission and estimated Offering expenses payable by the Company. In addition, Cardiome has also granted the underwriters of the Offering a 30-..."/>
Cardiome Announces Pricing of Public Offering of 10,000,000 Common Shares
Guided Therapeutics, Inc., the maker of a rapid and painless testing platform based on its patented biophotonic technology, today announced that it shipped four additional LuViva ® Advanced Cervical Scan systems to Bangladesh for use in the country’ s cervical cancer screening program. This brings to 12 the number of LuVivas and more than 1,000 disposable Cervical Guides shipped to Bangladesh. “With this shipment, we will have 12 LuVivas in Bangladesh which..."/>
Guided Therapeutics Ships Additional LuViva® Advanced Cervical Scan Systems and Disposables to Bangladesh
Chembio Diagnostics revealed on Monday that it expects its operating loss to be in the range of USD2.30m to USD2.50m for Q2 2016.. Additionally, the company expects to report total revenue in the range of USD3.20m to USD3.30m for the three months ended 30 June 2016.. Including non-cash expense for the valuation allowance, the company estimates net loss in the range USD8.30m to USD8.50m for the three months ended 30 June 2016.."/>
Chembio Diagnostics anticipates Q2 2016 operating loss in USD2.30m to USD2.50m range
Cumulus Media's 100.7 WLEV and CAT Country 96 are partnering with CareerLink, Sands Casino Resort, the Greater Lehigh Valley Auto Dealers Association, Yocco's and Phillips Pet Food& Supplies for the event."/>
Job fair to be held today at the Lehigh Valley Mall [The Morning Call (Allentown, Pa.)]
Enzymotec Ltd.,, a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that the Company will release financial results for the second quarter ended June 30, 2016 on Tuesday, August 9, 2016, before the market opens. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will host a conference call to review..."/>
Enzymotec to Report Second Quarter 2016 Financial Results
Progenics Pharmaceuticals, Inc. announced today that it has received a $50 million milestone payment from its worldwide collaboration partner, Valeant Pharmaceuticals International, Inc., resulting from the US Food and Drug Administration's marketing approval last week of RELISTOR ® Tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain. “We are pleased that our partner Valeant can now offer..."/>
Progenics Receives $50 Million Milestone Payment Following FDA Approval of RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain
Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced that the US Food and Drug Administration has conditionally accepted the proprietary brand name,“ Gimoti,” for the Company’ s product candidate, EVK-001. A request for proprietary name review for Gimoti will be included if and when Evoke submits a New Drug Application for the product candidate. The name Gimoti was developed..."/>
Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001
BioTelemetry, Inc., the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce that it has received U.S. Food and Drug Administration 510 clearance of its next generation Mobile Cardiac Outpatient Telemetry™ device, the MCOT™ Patch. The MCOT™ Patch is a four-lead, two-channel system which provides the same best in class technology as the current..."/>
BioTelemetry, Inc. Announces FDA Approval of Its Next Generation Device, the MCOT™ Patch
Air Methods Corporation today announced preliminary financial and operating results for its second quarter ended June 30, 2016. Results are subject to final quarter-end closing and review procedures and are subject to change.. The Company anticipates revenues for the second quarter of 2016 will increase by 11.0% to approximately $293 million compared to revenues of $264 million in the prior year period."/>
Air Methods Provides Update on 2nd Quarter Results
WellCare Health Plans, Inc., has provided a $75,000 grant to help fund a one-year asthma quality improvement project conducted by the Georgia Chapter of the American Academy of Pediatrics. The project was designed to improve asthma care in pediatric practices by better understanding the most effective ways to promote the implementation, adoption and spread of evidenced-based practices."/>
WellCare Applauds Encouraging Outcomes from Georgia Pediatricians' Asthma Quality Improvement Project
Growblox Sciences, Inc. is pleased to announce that an entity associated with Pacific Leaf Partners LLC, the strategic partner that financed the buildout of the Teco Avenue cultivation facility in Las Vegas, has completed the purchase of that building. In connection with the purchase, the initial term of the GBLX lease covering the facility was extended to ten years, with an optional five-year extension. GBLX has also entered into a preliminary..."/>
Growblox Sciences, Inc. with Pacific Leaf Partners LLC, Announces Ownership of Flagship Teco Medical Cannabis Growing Facility
Trovagene, Inc., a developer of circulating tumor DNA molecular diagnostics, today announced the publication of study results that demonstrate the clinical and analytical validity of the Trovera™ urine- and blood based liquid biopsy tests to assess EGFR T790M mutational status http://www.jto.org/article/S1556-0864 30587-1/ abstract. The data show that the Trovera™ test, using proprietary mutation allele enrichment technology,..."/>
Diagnostic Performance of Urinary EGFR Testing in Lung Cancer Patients Published in Journal of Thoracic Oncology
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company..."/>
VBL Therapeutics to Report Second Quarter 2016 Financial Results on August 15
Tandem Diabetes Care ®, Inc., a medical device company and the manufacturer of the t: slim ®, t: slim G4™ and t: flex ® Insulin Pumps, today announced FDA clearance of an expanded pediatric indication for the t: slim ® Insulin Pump, lowering its use to children age 6 and older from children age 12 and older. The t: slim Pump is the first and only touchscreen insulin pump cleared by the U.S. This expanded pediatric indication applies to the current t: slim Pump features, with no changes..."/>
Tandem Diabetes Care® Announces Expanded Pediatric Indication of t:slim® Insulin Pump for Ages 6 and Older
Varian Medical Systems, today announced medical dosimetrists using its Eclipse™ treatment planning software created the top scoring photon and proton radiotherapy treatment plans in the 2016 American Association of Medical Dosimetrists and Radiosurgery Society Plan Study. In addition to these two awards, Eclipse was also used to create the top five scoring photon treatment plans. With the goal of helping drive out variation and..."/>
Varian Eclipse Software Users Take Top Spots in Treatment Plan Study
Chembio Diagnostics said on Monday that it proposes to launch an underwritten public offering of USD10.0m of its common stock. The company intends to provide the underwriters with a 30- day option to purchase additional shares equal to up to 15% of the aggregate number of shares to be sold in the offering to cover over-allotments, if any. Craig-Hallum Capital Group LLC is acting as sole book-running manager for the proposed offering."/>
Chembio Diagnostics expects USD10.0m from public offering of common stock
Cardiome Pharma reported on Monday that it plans to commence an underwritten public offering of shares of its common stock. The company said it intends to provide the underwriters of the offering with a 30- day option to purchase additional shares of its common stock in an amount up to 15% of the shares sold in the offering on the same terms and conditions. Net proceeds from the offering may be used by the company for the in-licensing of dalbavancin,..."/>
Cardiome to issue common stock in public offering

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials645 Articles
Information Technology604 Articles
Consumer Discretionary563 Articles
Industrials440 Articles
Health Care393 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.